Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) EBIT (2020 - 2026)

Elicio Therapeutics filings provide 4 years of EBIT readings, the most recent being -$9.4 million for Q4 2023.

  • On a quarterly basis, EBIT fell 57.56% to -$9.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$35.7 million, a 10.16% decrease, with the full-year FY2025 number at -$37.7 million, up 16.17% from a year prior.
  • EBIT hit -$9.4 million in Q4 2023 for Elicio Therapeutics, up from -$10.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $14.6 million in Q4 2021 to a low of -$19.9 million in Q1 2021.
  • Median EBIT over the past 4 years was -$11.2 million (2020), compared with a mean of -$10.2 million.
  • Biggest five-year swings in EBIT: skyrocketed 205.66% in 2021 and later tumbled 140.73% in 2022.
  • Elicio Therapeutics' EBIT stood at -$13.8 million in 2020, then skyrocketed by 205.66% to $14.6 million in 2021, then tumbled by 140.73% to -$6.0 million in 2022, then crashed by 57.56% to -$9.4 million in 2023.
  • The last three reported values for EBIT were -$9.4 million (Q4 2023), -$10.8 million (Q3 2023), and -$7.8 million (Q2 2023) per Business Quant data.